ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion
Cellular Oncology · 2026
DOI: 10.1007/s13402-026-01204-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2026. Verfasst von Jiwei Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoadjuvant Therapy, Chemokine CCL2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: a key project jointly built by the provincial and ministerial authorities of the Health Commission of Henan Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450008, China.
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450008, China. xingwenqun1967@163.com.
Förderung
- a key project jointly built by the provincial and ministerial authorities of the Health Commission of Henan Province
Zitieren
APA
Cheng, J., Ma, H., Qian, X., & Xing, W. (2026). ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion. Cellular Oncology. https://doi.org/10.1007/s13402-026-01204-7
Vancouver
Cheng J, Ma H, Qian X, Xing W. ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion. Cellular Oncology. 2026. doi:10.1007/s13402-026-01204-7
BibTeX
@article{Cheng2026,
author = {Cheng, Jiwei and Ma, Haibo and Qian, Xin and Xing, Wenqun},
title = {ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion},
journal = {Cellular Oncology},
year = {2026},
doi = {10.1007/s13402-026-01204-7}
}
EUVIMED